← Eichor
Study identifier: NCT06137378 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]

Condition: Squamous Cell Carcinoma of Head and Neck · Hypopharyngeal Squamous Cell Carcinoma · Laryngeal Squamous Cell Carcinoma Stage III  ·  Sponsor: University of Leipzig

PhasePhase 2
Planned participants140
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

ELOS is a prospective, randomized, open-label, controlled, two-armed parallel group, phase II multicentre trial in local advanced stage III, IVA/B head and neck squamous cell carcinoma of the larynx or hypopharynx (LHNSCC) with PD-L1-expression within tumor tissue biopsy, calculated as CPS ≥ 1 curable by total laryngectomy. Induction chemotherapy (IC) with Docetaxel and Cisplatin (TP) followed by radiation will be compared to additional PD-1 inhibition. Patients will be selected after short induction early response evaluation after the first cycle IC (IC-1) aiming on larynx organ-preservation by additional 2 cycles IC followed by radiotherapy (69.6 Gy) for responders achieving endoscopic estimated tumor surface shrinkage (ETSS) ≥ 30%. Nonresponders (ETSS \< 30% or progressing disease) will receive total laryngectomy and selective neck dissection followed by postoperative radiation or chemoradiation according to the recommendation of the clinics multidisciplinary tumor board. However, Patients randomized into the intervention arm starting day 1 will receive 200 mg Pembrolizumab (MK-3475) i.v. in 3-week cycle (q3w) for 17 cycles (12 months). Treatment with pembrolizumab will continue in the experimental arm regardless of ETSS status after IC-1 in both responders and laryngectomized nonresponders, independent from subsequent decision on adjuvant therapy after TL.

This description comes directly from the study's public registry record.

Talk to the study team

Andreas Dietz, MD PhD  ·  +493419721700  ·  Andreas.Dietz@medizin.uni-leipzig.de

Susanne Wiegand, MD PhD  ·  +493419721700  ·  susanne.wiegand@medizin.uni-leipzig.de

Always discuss trial participation with your own doctor first.

Locations (9)

Universitätsklinikum Mannheim, Klinik für Hals-Nasen-Ohrenheilkunde Theodor-Kutzer-Ufer 1-3Mannheim, Baden-Würtemberg, GermanyRecruiting
Universitätsklinikum Ulm / Ulm University Medical Center, Klinik für Hals- Nasen-Ohrenheilkunde und Kopf-Halschirurgie, Frauensteige 12Ulm, Baden-Würtemberg, GermanyRecruiting
Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Ismaninger Straße 22München, Bavaria, GermanyNot Yet Recruiting
Universität Regensburg, Klinik und Poliklinik für Strahlentherapie Franz-Josef-Strauss-Allee 11Regensburg, Bavaria, GermanyRecruiting
Universitätsklinikum Würzburg, Klinik für Hals-, Nasen-, Ohrenheilkunde, Josef-Schneider-Straße 8Würzburg, Bavaria, GermanyRecruiting
Klinikum Ernst von Bergmann, Klinik für Hämatologie, Onkologie und Palliativmedizin, Charlottenstr. 72Potsdam, Brandenburg, GermanyNot Yet Recruiting
Universitätsklinikum Köln, Klinik für Hals-, Nasen-, Ohrenheilkunde, Kerpener Str. 62Cologne, North Rhine-Westphalia, GermanyNot Yet Recruiting
University of Leipzig, Department für Kopf- und Zahnmedizin, Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Liebigstrasse 12Leipzig, Saxon, GermanyRecruiting
Universitätsklinikum Jena Klinik für Hals-, Nasen- und Ohrenheilkunde, Am Klinikum 1Jena, Thuringia, GermanyNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06137378